Skip to content
StackItSmart
CCase reports / series

HMG

Menotropins · Human Menopausal Gonadotropin

HMG (human menopausal gonadotropin, menotropins) is an injectable, urine-derived hormone preparation that contains follicle-stimulating hormone (FSH) activity together with luteinizing hormone (LH) activity (in many modern preparations the LH activity is supplied by added hCG). It is an approved fertility drug whose established, evidence-supported use in men is to supply FSH for the induction of sperm production in secondary (hypogonadotropic) hypogonadism, essentially always given together with hCG. In the harm-reduction context it is used off-label as an ancillary to try to restore spermatogenesis and testicular function after anabolic-androgenic steroid (AAS)-induced shutdown, but there are no randomized trials in that specific population and the evidence is extrapolated from congenital/pituitary hypogonadism plus reviews and case reports. The main risks are that it is a prescription biologic injection that raises testosterone and estradiol, so it can drive gynecomastia and breast tenderness; it carries injection-site and hypersensitivity reactions; a theoretical thromboembolic risk exists because gonadotropins can be prothrombotic; and self-directed use without an endocrinologist risks masking or mismanaging underlying pituitary/testicular disease. It is not a performance or physique drug and provides no anabolic benefit on its own.

Clinical readoutAncillary · gonadotropin
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
30 h
Route
Intramuscular or subcut…
Evidence
C
Active
Pharmacologic FSH expos…
30 h2.5 d3.8 d5 d6.3 d
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ FSH glycoprotein component: elimination is slow; population PK in humans found an intravenous mean residence time of ~16-18 h, but after intramuscular/subcutaneous injection absorption is rate-limiting (mean absorption time ~27-48 h), so the effective apparent half-life after a standard injection is on the order of ~1-1.5 days. LH activity has a shorter half-life; any added hCG component is longer-acting (~24-36 h).
Pharmacology

Mechanism of action

Menotropins deliver exogenous FSH and LH-type activity to the gonad. In men the FSH component acts on Sertoli cells to support the seminiferous tubule environment required for quantitatively normal spermatogenesis, while the LH activity (native LH or added hCG) stimulates Leydig cells to produce intratesticular testosterone. Because hCG/LH alone can maintain but not fully restore sperm output, FSH from HMG is added to achieve quantitatively normal spermatogenesis. It works downstream of the pituitary, so it can stimulate the testis even when the hypothalamic-pituitary axis is suppressed (as after AAS use or in pituitary failure). It does not restart the body's own gonadotropin secretion.
Kinetics

Pharmacokinetics

Half-life

FSH glycoprotein component: elimination is slow; population PK in humans found an intravenous mean residence time of ~16-18 h, but after intramuscular/subcutaneous injection absorption is rate-limiting (mean absorption time ~27-48 h), so the effective apparent half-life after a standard injection is on the order of ~1-1.5 days. LH activity has a shorter half-life; any added hCG component is longer-acting (~24-36 h).

Active duration

Pharmacologic FSH exposure persists roughly 1-3 days per injection, which is why dosing is typically given several times per week rather than daily. The biological endpoint (appearance of sperm) lags far behind and generally requires months of continuous therapy.

Route

Intramuscular or subcutaneous injection only (not orally active).

Metabolism & clearance

Cleared largely by the kidney as a glycoprotein hormone, with urinary excretion of intact hormone plus catabolic breakdown; human PK estimated FSH clearance ~0.33 l/h. Relevant for washout/monitoring, not for any test-evasion purpose.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Supplies FSH activity that, combined with hCG/LH activity, induces and supports sperm production in men with secondary (hypogonadotropic) hypogonadism
  • Increases testicular volume during therapy (roughly doubling over 5-12 months in hypogonadotropic men)
  • Raises intratesticular and serum testosterone via LH/hCG-driven Leydig cell stimulation
  • In the harm-reduction (post-AAS) setting it is used off-label attempting to recover spermatogenesis, but this specific use is supported only by reviews/case reports, not controlled trials
  • Provides no independent anabolic, fat-loss, or performance effect
Safety

Adverse effects by system

Cardiovascular

No direct cardiotoxicity established in men. A theoretical prothrombotic/thromboembolic risk is attributed to gonadotropin therapy generally; robust human cardiovascular safety data specific to male HMG use are lacking.

Hepatic

No meaningful hepatotoxicity reported; HMG is an injected peptide/glycoprotein and is not liver-metabolized like oral 17-alpha-alkylated steroids. No adequate human hepatic-injury data signal exists.

Endocrine / HPTA

HMG acts on the testis, not the pituitary, so it does not itself restart endogenous LH/FSH secretion and does not treat the underlying hypothalamic-pituitary suppression seen after AAS use. It raises testosterone and estradiol; supraphysiologic testosterone and elevated estradiol can occur.

Reproductive

Intended reproductive effects (spermatogenesis, increased testicular volume). Adverse reproductive-related effects include gynecomastia and breast tenderness driven by increased testosterone aromatization to estradiol.

Neuropsychiatric

No well-characterized psychiatric adverse-effect profile in the male HMG literature; mood changes tied to shifting testosterone/estradiol are plausible but not established. No adequate human data.

Renal

No specific nephrotoxicity described; the kidney is the main clearance route. No adequate human data indicating renal injury.

Hematologic

No robust male-specific hematologic adverse data; androgen elevation could theoretically raise hematocrit via increased testosterone, but this is not well documented for HMG specifically. No adequate human data.

Dermatologic

Injection-site reactions and skin reactions are reported (e.g., allergic erythema); acne can occur, attributable to the rise in testosterone during cyclical hCG/HMG therapy.

Recovery

HPTA suppression & recovery

Suppression: Not directly suppressive of the axis, but does not restore it either

HMG substitutes for pituitary gonadotropins at the testis; it does not stimulate the hypothalamus or pituitary and therefore does not by itself restart a suppressed HPTA (for example after AAS use). Restoration of the body's own axis is a separate process. Any attempt at fertility restoration or axis recovery after AAS or in hypogonadism should be directed by an endocrinologist or reproductive urologist, with individualized diagnosis, baseline bloodwork, and monitoring. If a SERM is used in a recovery plan, only a single SERM under clinician supervision should be considered; dual-SERM regimens are not advised. This is conservative, general information and not a protocol.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Serum total testosteroneEstradiolLH and FSHSemen analysis (sperm concentration/motility)CBC / hematocritTesticular volume assessment (exam or ultrasound)

Cadence: Baseline full endocrine and metabolic workup before starting, then reassessment roughly every 1-3 months during therapy; spermatogenesis endpoints assessed over months, since sperm may take many months to appear.

Warning signs — seek care
  • New or worsening breast enlargement or breast tenderness (gynecomastia)
  • Signs of a blood clot: calf swelling/pain, chest pain, shortness of breath, sudden severe headache or vision change (seek emergency care)
  • Severe injection-site reaction, rash, or signs of allergic reaction
  • Marked acne or rapid mood change
  • Symptoms of very high testosterone/estradiol
  • Any symptom prompting the underlying pituitary/testicular condition to be re-evaluated by a clinician
Do not use if

Contraindications

  • Known hypersensitivity to menotropins or urinary-derived gonadotropin preparations
  • Androgen- or hormone-dependent malignancy (e.g., prostate cancer, male breast cancer) because therapy raises testosterone/estradiol
  • Uncontrolled or undiagnosed pituitary/hypothalamic tumor or other undiagnosed endocrine disease
  • Personal or high thrombophilic risk / prior thromboembolism (theoretical gonadotropin-associated prothrombotic caution)
  • Primary (testicular) failure, where the testis cannot respond and gonadotropin therapy is ineffective
  • Use without medical supervision or without a diagnostic workup
Combinations

Interaction profile

  • ModerateWith another gonadotropin (hCG / hMG): Hormonal
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Treat HMG as a prescription biologic that requires an endocrinologist or reproductive urologist, a baseline diagnostic workup, and lab monitoring; it is not a self-managed physique or performance drug.
  • It acts on the testis and does not restart your own pituitary axis, so it does not by itself fix AAS-induced shutdown; the underlying suppression must be evaluated separately.
  • Get baseline and follow-up bloodwork (testosterone, estradiol, LH, FSH, CBC/hematocrit) and semen analysis; response is judged over months.
  • Watch for and report gynecomastia/breast tenderness, which reflect rising estradiol from the testosterone the therapy stimulates.
  • Stop and seek emergency care for signs of a blood clot (leg swelling/pain, chest pain, shortness of breath, sudden severe headache or vision changes) or a severe allergic/injection reaction.
  • Do not combine with exogenous testosterone if fertility is a goal, since testosterone suppresses sperm production.
  • Any recovery plan involving a SERM should use a single SERM under clinician guidance; dual-SERM regimens are not advised.
  • Evidence for HMG in the post-AAS recovery setting is weak (no randomized trials); do not assume guaranteed fertility restoration.
Evidence

Citations (10)

Every clinical claim above is tied to a primary source. Overall evidence grade C — graded to the best available evidence for its core claims.

  1. 01

    HMG (menotropins) supplies FSH activity and, combined with hCG, is used to induce spermatogenesis in men with secondary/hypogonadotropic hypogonadism; hCG alone maintains but does not quantitatively sustain sperm production, so FSH is needed for quantitatively normal spermatogenesis

    CohortPMID 12444893 ↗

  2. 02

    hCG/hMG therapy induced sperm in the ejaculate in 54/57 treatment courses and doubled bilateral testicular volume within 5-12 months in men with secondary hypogonadism, with pregnancies in 26/36 courses

    CohortPulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases.PMID 9758439 ↗

  3. 03

    Cyclical hCG/HMG therapy in hypogonadotropic men produced spermatogenesis in ~83% of patients and was associated with a tendency to higher serum testosterone and more facial acne and breast tenderness, plus skin/allergic reactions in the injection-based groups

    CohortDOI 10.1177/1557988318818280 ↗

  4. 04

    Some hypogonadotropic men respond poorly to combined hCG/HMG gonadotropin therapy even after ~12 months, illustrating that gonadotropin therapy does not universally restore sperm production

    CohortDOI 10.20945/2359-4292-2023-0101 ↗

  5. 05

    For secondary (hypogonadotropic/normogonadotropic) hypogonadism, management options to preserve fertility include hCG with or without hMG/FSH, and exogenous testosterone should be avoided in men seeking fertility because it impairs spermatogenesis

    ReviewDOI 10.1002/smrj.4 ↗

  6. 06

    Anabolic-androgenic steroid use can cause symptomatic hypogonadism; management of AAS-induced hypogonadism/fertility uses agents including hCG, hMG/FSH, and selective estrogen receptor modulators, and no quality controlled studies met inclusion criteria (evidence is limited)

    ReviewAnabolic steroid-induced hypogonadism: diagnosis and treatment.DOI 10.1016/j.fertnstert.2014.02.002 ↗

  7. 07

    AAS-induced male infertility can be managed with combinations that may include hCG, FSH (rFSH), aromatase inhibitors and SERMs to recover spermatogenesis, but additional studies are needed and users often lack awareness of fertility risks

    ReviewAnabolic steroid misuse and male infertility: management and strategies to improve patient awareness.DOI 10.1080/17446651.2021.1921574 ↗

  8. 08

    AAS abuse can cause hypogonadotropic hypogonadism that is not always reversible after discontinuation, and gonadotropin (hCG) treatment does not guarantee recovery

    Case reportDOI 10.5980/jpnjurol1989.99.729 ↗

  9. 09

    Human population pharmacokinetics of urinary FSH: two-compartment disposition with slow clearance (~0.33 l/h), IV mean residence time ~18 h, and absorption-limited kinetics after IM/SC injection (mean absorption time ~27-48 h)

    RCTDOI 10.1046/j.1365-2125.1998.00644.x ↗

  10. 10

    Gonadotropin administration is indicated for gonadotropin deficiency/GnRH resistance and acts at the gonad to stimulate spermatogenesis, downstream of the pituitary

    ReviewDOI 10.1007/s11102-006-0416-5 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice